C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel | Zendy

Megan Melody | Zendy; Zaid Abdel Rahman | Zendy; Hollie Saunders | Zendy; Paula A. Lengerke-Diaz | Zendy; Nicole Gan | Zendy; Allison Rosenthal | Zendy; Ernesto Ayala | Zendy; Han W. Tun | Zendy; Hemant S. Murthy | Zendy; Vivek Roy | Zendy; James M. Foran | Zendy; Januario E. Castro | Zendy; Pramod Guru | Zendy; Mohamed A. KharfanDabaja | Zendy

Open Access

C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel

Author(s) -

Megan Melody,

Zaid Abdel Rahman,

Hollie Saunders,

Paula A. Lengerke-Diaz,

Nicole Gan,

Allison Rosenthal,

Ernesto Ayala,

Han W. Tun,

Hemant S. Murthy,

Vivek Roy,

James M. Foran,

Januario E. Castro,

Pramod Guru,

Mohamed A. KharfanDabaja

Publication year - 2020

Publication title -

hematology/oncology and stem cell therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.666

H-Index - 22

eISSN - 1658-3876

pISSN - 2589-0646

DOI - 10.1016/j.hemonc.2020.09.004

Subject(s) - ferritin , medicine , intensive care unit , cancer research , chemistry

Chimeric antigen receptor (CAR) T-cell is an effective therapy in relapsed/refractory large B-cell lymphomas that, due to its unique toxicities, often requires escalation of care to the intensive care unit (ICU) setting. C-reactive protein (CRP) and ferritin are serum inflammatory markers associated with onset and persistence of CAR T-cell-related toxicity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research